The analysis of the relationship between circulating HS/H and selected endothelial dysfunction markers (sVACAM-1, MCP-1, MMP-9 and ADMA), as well as clinical (DAS 28-ESR, SW, TEN, VAS) and laboratory (ESR, CRP) indicators of disease activity in RA patients, at the beginning and after 15 months of anti-TNF-α therapy, are presented in Table 4. The gene discussed is MMP9; the disease is endothelial dysfunction.